Northern Trust
ARCT icon

Northern Trust’s Arcturus Therapeutics ARCT Stock Holding History

Northern Trust’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Sell
204,578
-15,035
-7% -$119K ﹤0.01% 3340
2026
Q1 		$1.7M Buy
219,613
+18,832
+9% +$137K ﹤0.01% 3061
2025
Q4 		$1.23M Sell
200,781
-17,053
-8% -$184K ﹤0.01% 3263
2025
Q3 		$4.01M Sell
217,834
-3,199
-1% -$51.4K ﹤0.01% 2633
2025
Q2 		$2.88M Sell
221,033
-29,018
-12% -$343K ﹤0.01% 2791
2025
Q1 		$2.65M Sell
250,051
-6,281
-2% -$99.7K ﹤0.01% 2771
2024
Q4 		$4.35M Buy
256,332
+13,582
+6% +$256K ﹤0.01% 2586
2024
Q3 		$5.63M Buy
242,750
+12,435
+5% +$266K ﹤0.01% 2407
2024
Q2 		$5.61M Sell
230,315
-6,627
-3% -$201K ﹤0.01% 2332
2024
Q1 		$8M Sell
236,942
-10,057
-4% -$356K ﹤0.01% 2186
2023
Q4 		$7.79M Buy
246,999
+18,235
+8% +$433K ﹤0.01% 2232
2023
Q3 		$5.84M Buy
228,764
+910
+0.4% +$28K ﹤0.01% 2351
2023
Q2 		$6.53M Buy
227,854
+15,682
+7% +$427K ﹤0.01% 2352
2023
Q1 		$5.09M Sell
212,172
-1,086
-0.5% -$19.5K ﹤0.01% 2466
2022
Q4 		$3.62M Buy
213,258
+5,863
+3% +$102K ﹤0.01% 2676
2022
Q3 		$3.07M Sell
207,395
-1,501
-0.7% -$25.2K ﹤0.01% 2773
2022
Q2 		$3.29M Buy
208,896
+15,187
+8% +$298K ﹤0.01% 2780
2022
Q1 		$5.22M Sell
193,709
-8,443
-4% -$215K ﹤0.01% 2565
2021
Q4 		$7.48M Sell
202,152
-3,118
-2% -$127K ﹤0.01% 2440
2021
Q3 		$9.81M Sell
205,270
-30,769
-13% -$1.38M ﹤0.01% 2281
2021
Q2 		$7.99M Sell
236,039
-8,259
-3% -$280K ﹤0.01% 2529
2021
Q1 		$10.1M Sell
244,298
-42,074
-15% -$2.51M ﹤0.01% 2287
2020
Q4 		$12.4M Buy
286,372
+43,457
+18% +$2.94M ﹤0.01% 2107
2020
Q3 		$10.4M Buy
242,915
+27,992
+13% +$1.39M ﹤0.01% 2089
2020
Q2 		$10M Buy
214,923
+177,363
+472% +$6.11M ﹤0.01% 2092
2020
Q1 		$510K Buy
37,560
+930
+3% +$11.9K ﹤0.01% 3443
2019
Q4 		$398K Buy
36,630
+13,899
+61% +$145K ﹤0.01% 3607
2019
Q3 		$233K Buy
+22,731
New +$246K ﹤0.01% 3721

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust's ARCT Position: Q2 2026 in Review

Northern Trust reduced its Arcturus Therapeutics (ARCT) stake by 6.8% in Q2 2026, selling an estimated $119K and leaving 204,578 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #3340.

Northern Trust first reported a position in ARCT in Q3 2019 and has held it in 28 quarters since. The position peaked at $12.4M in Q4 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Northern Trust held 204,578 shares of Arcturus Therapeutics worth $1.37M as of Q2 2026.
  • Northern Trust sold 15,035 Arcturus Therapeutics shares in Q2 2026, an estimated $119K.
  • Arcturus Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3340 holding.
  • Northern Trust first reported a position in Arcturus Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • Northern Trust's Arcturus Therapeutics position peaked at $12.4M in Q4 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.